Insolation Energy — a cheap module-maker racing the clock
Insolation Energy Ltd
Snapshot
Insolation Energy (brand “INA Solar”) makes solar panels in Jaipur. It started in 2015 stamping out 200 MW of panels and has, in a blur, become a ~5.5 gigawatt module-maker — top-10 in India by size, though a minnow next to the giants. Market cap ₹2,577 cr, price ₹117 (52-week range ₹79.8–₹282), trading at P/E 12.8 and P/B 3.2, on RoE 28.2% and RoCE 22.2%. What kind of animal is it? A fast-growing, capital-hungry, commodity manufacturer — currently profitable and protected by government policy — that is betting borrowed money on climbing up the value chain before the protection fades. As of 2026-06-20, from screener snapshot.
The verdict in two boxes — the business first, the price second
Box 1 — The business (durable):
| Lens | Result |
|---|---|
| Business-quality score | 15.5 / 23 (Quality 7.0/12 · Growth 5.0/6 · Longevity 3.5/5) |
| Buffett rubric | ~3 / 10 PASS-equivalent |
| Business bucket | Good, leaning Gruesome (decent returns today, but capital-hungry and commodity-priced) |
| Wealth-creator type | Transitory · Volatile (policy-and-cycle driven; too young to call Enduring) |
| Economic Profit | +₹131 cr (RoE 28.2% − CoE 12% × ₹807 cr net worth) — creating value on paper |
A Good-but-capital-hungry business whose quality case rests almost entirely on growth and a policy tailwind — not on a moat. That judgement holds whether the share costs ₹117 or ₹282.
Box 2 — The price today (a current phenomenon):
| Reading | Result |
|---|---|
| CMP | ₹117 (as of 2026-06-20) |
| Price pillar | 2 / 2 (PEG ~0.2–0.4 · 5-yr payback ~1.1x) — cheap on the mechanical math |
| Margin-of-safety band | ₹90–₹130 (risk-haircut for cyclicality/execution; raw PEG-math allows higher) |
| Mr. Market’s mood now | Fearful — down ~58% from its ₹282 high even as profits rose 60% |
| CMP vs the band | Fair, mid-band — cheap if the cell plant delivers, ordinary if it doesn’t |
Today the market prices it cheaply — a mood driven by an SME-era boom-and-bust unwind and worry about a solar glut, not by any collapse in the business. That mood can flip while the business above stays exactly the same.
In plain English
Imagine a workshop that buys solar “cells” — the little squares that actually turn sunlight into electricity — wires them together behind glass, frames them in aluminium, and sells the finished panel. That assembly step is most of what Insolation does today. It’s honest work, and they’ve grown it astonishingly fast: revenue went from ₹215 cr to ₹2,146 cr in four years, and profit from ₹7 cr to ₹201 cr. But here’s the catch — assembling panels is a low-margin, crowded trade. Insolation earns about ₹13 of profit on every ₹100 of sales. The companies that also make the cells earn two to four times that. The panel is the commodity; the cell is where the money is.
So the whole story is one bet: can Insolation become a cell-maker before the easy money in panels runs out? They’ve borrowed heavily — debt jumped from ₹108 cr to ₹888 cr in a single year — to build a ₹1,512 cr cell factory in Madhya Pradesh, due to start late 2026. If it works, their profit margin should jump from ~14% to ~20%, and they’d be protected by a new rule (from 1 June 2026) that forces government solar projects to use Indian-made cells. If it slips, they’re a sub-scale panel assembler carrying a big loan into what regulators themselves are calling a manufacturing bubble.
The moat question is the uncomfortable one. Right now there is no real moat — the panel price is set by the dollar and the market, not by Insolation’s brand. Their protection is a government rule, and rules can change. The thing they’re building (their own cells) would give them a genuine cost advantage — but it isn’t built yet, and ten other Indian companies, several far bigger and already integrated (Waaree, Premier, Adani), are building the same thing.
The tension in one line: on the numbers, the stock looks dirt cheap (13× earnings for a company growing 60%); on the business, it’s a commodity manufacturer with thin defences making a debt-funded leap it hasn’t landed yet. Cheap and risky are both true at once. The price already tells you the market knows it.
Sitting down with the management
Dear reader — if Mr. Agrawal and I spent an afternoon with these two, we’d come away liking them more than we expected, and trusting the balance sheet a little less.
First, the good news, and it’s real. Insolation is run by two founders, not one — Vikas Jain (Managing Director) and Manish Gupta (Chairman), each owning roughly a third, together about 66%. That matters: a two-man company is sturdier than a one-man show, and these two have every rupee of their own net worth riding alongside yours. The skin-in-the-game tests all pass cleanly: promoter holding is high, pledging is zero, and — the tell that matters most — they did not sell a single share into the run to ₹282. Vikas Jain’s family vehicle actually bought stock on the open market in February 2026. Their pay is modest and flat (~₹2.5–3 cr between them, about 5% of profit) and didn’t balloon when profit grew tenfold. The audit is clean, no regulator has come knocking, and the topline has beaten what they guided, year after year. Buffett looks for “brains, passion and integrity”; on passion and apparent integrity, these two show up.
Now the part that would make us sit back in our chairs. This management leans empire-builder. Listen to the 2018 Vikas Jain — a craftsman boasting that of 200,000 panels shipped, only two drew a complaint. Listen to the 2025 version — “market leader in all segments,” cells and modules and aluminium frames and ingots and wafers and EV charging and battery storage and perovskite, exports to three continents, all at once. That is the “everything everywhere” roadmap that has sunk more ambitious manufacturers than it has made. Buffett’s warning rings here: the best businesses do next year what they did last year; this one is sprinting in six directions.
And the governance plumbing has hairline cracks — not a burst pipe, but the kind of thing that tells you who these people are. Two of the eight board seats labelled “non-executive” are filled by employees of Fluidcon Engineers — the promoters’ own family pipe-fittings business. That is not arm’s-length oversight; that is family at the table wearing a name badge that says “independent-ish.” When they raised ₹395 cr in a 2024 share sale, the monitoring agency noted the board never formally approved reallocating the money, and the rating agency flagged “fund commingling” it couldn’t independently verify. The auditor is a small Jaipur firm — fine at ₹200 cr of revenue, light for a company whose debt just multiplied eight-fold. And screener’s “capitalizing interest cost” flag is structurally plausible: when you’re building a giant plant on borrowed money, a slice of the interest can be parked on the balance sheet instead of run through the profit line — which quietly flatters reported profit. We couldn’t size it (the annual-report PDFs wouldn’t surrender the CWIP and finance-cost notes), so we flag it honestly rather than dismiss or inflate it.
The forensic check that does fire loudly is the cash. Over five years the company reported ₹400 cr of profit but generated only ₹78 cr of operating cash — and last year operating cash was negative ₹73 cr. That is the classic “credit the P&L, debit the balance sheet” shape: profit is real on paper, but it’s tied up in receivables (up 156% to ₹280 cr) and inventory rather than landing in the bank. Management’s answer is fair — you’re seeing a company in a furious growth-and-capex phase, and they expect free cash to turn positive 6–8 months after the cell plant runs. That’s a reasonable explanation. It is also exactly what every cash-hungry grower says, and you only know if it was true in hindsight.
Would Buffett and Agrawal shake hands on this management? A cautious half-handshake. The integrity signals (no pledge, no selling, modest pay, clean audit) are genuinely reassuring and rare. But the thin board independence, the disclosed-and-downplayed related-party flows, the eight-fold debt build for an unproven bet, and the sprawling ambition would keep their hands near their wallets. What would change their mind: the cell plant commissioning on time and on budget, free cash flow turning positive as promised, the “non-executive” family directors replaced by genuine outsiders, and a year or two of profit that actually becomes cash.
What’s on the horizon (live-issues tracker)
Three live bets will decide the next two years. The first is the whole ballgame and gets the full interrogation.
① The crux — can a sub-scale module assembler turn itself into an integrated cell-maker before the glut hits? 🟡
“This investment works if and only if Insolation gets its own cell line running — at scale, on cost — before the panel-assembly margin it lives on today gets competed away.”
The mechanism, in plain terms. A solar panel has two economic halves. The cell (the silicon square that does the physics) is hard to make — capital-heavy, technical, and currently scarce in India. The module (wiring cells behind glass in a frame) is easy — anyone with a clean room and capital can do it, which is why ~165 GW of Indian module capacity is chasing ~50 GW of demand. Today Insolation buys cells and sells modules, so it sits on the easy, crowded, low-margin half. Its 14% margin versus integrated peers’ 22–41% is that gap, in one number. Building its own 4.5 GW cell plant moves it onto the hard, scarce, high-margin half — and qualifies it for the protected government market under the new cell-sourcing rule (ALMM List-II, live since 1 June 2026).
Test the analogy. Is this like a baker who buys flour deciding to grow his own wheat? Partly — backward integration into a scarce input is genuinely margin-accretive while the input is scarce. But here’s where the analogy breaks and the risk shows: everyone is planting wheat at once. India’s cell capacity is set to go from ~18 GW today to ~100 GW by end-2027. The scarcity rent Insolation is betting on — the very thing that makes the cell plant lucrative — is scheduled to evaporate on roughly the same timeline as the plant comes up. So the bet isn’t just “can we build it”; it’s “can we build it and fill it and still earn a premium once the cell shortage that justified it is gone.”
The named competition — Insolation is a minnow among whales:
| Player | Module scale | Integration | Valuation (Jun 2026) | Proof point |
|---|---|---|---|---|
| Waaree Energies | ~12 GW (→20 GW) | cells + wafers/ingot | ₹89,900 cr · P/E 23 · OPM 22% | Largest; PLI winner |
| Premier Energies | ~11 GW | strong cell base | ₹49,000 cr · P/E 33 · OPM 30% | Added 5.6 GW TOPCon cells Mar 2026 |
| Adani Solar | ~4 GW Mundra | fully integrated | (Adani group) | Group balance sheet |
| Websol Energy | cell-led | cell + module | ₹4,546 cr · P/E 15 · OPM 41% | 41% margin = the cell premium, visible |
| Vikram Solar | ~rev ₹4,800 cr | expanding into cells | ₹7,262 cr · P/E 15 · OPM 19% | Listed Aug 2025 |
| Insolation | ~5.5 GW | cells in build-out | ₹2,577 cr · P/E 13 · OPM 13% | Cell COD targeted late 2026 |
Look at Websol: a smaller company than Insolation by revenue, earning a 41% operating margin because it’s cell-led. That is the prize Insolation is chasing — and the proof it’s real. But look at Waaree and Premier: 12 GW and 11 GW, already integrated, flush with PLI money and R&D. In a glut, scale and cost-per-watt win, and a 5.5 GW player cannot out-cost a 20 GW one.
The real-world precedent — and it’s sobering. China is the ghost of solar-future. Chinese module prices fell ~38% to $0.085–0.095/W as ~900 GW of capacity (enough to supply the world to ~2032) flooded the market. The result: China’s top four makers lost $1.54 billion combined in H1 2025; LONGi’s module margin went negative. That is what an unprotected, overbuilt module business does — it sells below cost. India is protected from that by import duties and ALMM today, but India is now building its own domestic version of the same overcapacity (165 GW vs 50 GW demand), and its own clean-energy ministry has urged banks to be cautious lending for new module capacity — a regulator effectively calling the top.
The follow-on questions, answered:
- Is the threat to volume or to price? Price first. Demand exists (rooftop, KUSUM, utility), so Insolation can likely sell its panels — but at a thinning margin as domestic supply floods. The squeeze is on the spread, not the order book.
- Which segment is protected, which is exposed? Cells are protected (still scarce); modules are exposed (glutted). This is precisely why integration is the right move — and why staying module-only is the wrong place to be.
- What is the incumbent (Insolation) doing, and is it credible? Building cells, aluminium frames, and planning wafers/ingots — credible in direction, unproven in execution. They’ve read the room correctly; the question is the clock.
- Has anyone moved yet? ICRA explicitly forecasts consolidation of smaller/pure-play module makers. The shake-out is named and dated, not hypothetical.
Honest verdict on the crux: not too hard — the picture is legible. Insolation is doing the right thing (integrating) for the right reason (the module half is commoditizing) at genuine risk (it’s sub-scale, debt-funded, and racing a closing window). It is a defensible bet with a real clock on it, not a sure thing and not a folly. The single most important thing an owner can watch is the cell plant’s commissioning date and ramp.
② The debt-and-cash-flow stretch 🟡
Borrowings went from ₹108 cr to ₹888 cr; peak debt this year is guided to ~₹1,500 cr. Net debt/equity is still a moderate ~0.5x, the big loan is a 7-year IREDA facility (8.95% post-commissioning) with a 12-month moratorium, and ₹300 cr sits in fixed deposits against the drawn portion. But free cash flow is deeply negative (−₹521 cr last year) and management’s “positive FCF 6–8 months after the cell plant” is a promise, not a fact. Status: manageable on paper, unproven in delivery.
③ The KUSUM / IPP detour 🟡
Alongside manufacturing, a subsidiary is building ~325 MW of solar power plants (KUSUM agri-pump projects), ~₹1,000 cr of capex for ~₹135 cr of first-year revenue. This is a different, lower-return, capital-heavy business bolted onto a manufacturer — the kind of diversification Buffett would eye warily. It adds revenue visibility but dilutes the focus and the return profile. Status: early, watch whether it earns its cost of capital.
The watch-list (check these next quarter):
- Cell plant commissioning — does it hit “late 2026 / Q4 FY27” or slip? (The whole thesis.)
- Operating cash flow — does it turn positive in FY27 as promised, or does the ₹400-vs-₹78 cr profit-to-cash gap persist?
- Blended EBITDA margin — does it move from 14% toward the promised 20% as cells ramp, or stall?
- Receivable days — pull back from 48, or keep climbing past 50?
- Peak debt — capped near ₹1,500 cr, or does the wafer/ingot plan push it higher?
- Board independence — are the two Fluidcon-employee “non-executive” directors ever replaced by genuine outsiders?
QGLP scorecard (the Motilal Oswal lens) — the receipts
| # | Question | Score | Evidence |
|---|---|---|---|
| Quality of Business | 3.0/6 | ||
| 1 | Large opportunity? | 1 | India solar TAM is multi-decade and enormous — installs ~45–50 GW/yr and rising |
| 2 | Industry structured favourably? | 0.5 | Module assembly is fragmented & commodity (OPM was 6% in FY22); only policy (ALMM/DCR) gives temporary structure |
| 3 | Defensible moat? | 0.5 | No franchise — non-DCR price is set by $/W (₹13–14). Distribution (700 partners) + ALMM listing = thin. RoE high but only ~4 yrs, not 7-of-10 |
| 4 | Return ratios >15% consistently? | 0.5 | RoE 28.2%, RoCE 22.2% — both >15% recently, but RoCE swung 48%→22% and history is short (FY23–26) |
| 5 | Asset-light? | 0 | The opposite — ₹2,500 cr capex this year, FCF −₹521 cr, fixed assets ballooning. A capital sink |
| 6 | Favourable terms of trade? | 0.5 | ToT ≈ 77% (debtor 48d / payable 62d) looks OK, but cash-conversion cycle is +66 days and receivables rising |
| Quality of Management | 4.0/6 | ||
| 7 | Unquestionable integrity? | 0.5 | Zero pledge, modest pay, clean audit — but thin board independence, fund-commingling flag, interest-cap flag, small auditor |
| 8 | Proven execution? | 1 | Scaled 200 MW → 5.5 GW; beat topline guidance four years running |
| 9 | Growth mindset & vision? | 1 | Aggressive backward integration (cell → frame → wafer/ingot); clear ambition |
| 10 | Superior capital allocation? | 0.5 | Reinvesting at high RoE, but 8x debt for an unproven bet, ₹395 cr raise with a process lapse, lower-return IPP detour |
| 11 | Succession plan? | 0.5 | Two co-founders (better than one), but thin second line; CFO churned Mar 2025 |
| 12 | Minority interests protected? | 0.5 | No promoter selling, no pledge; but preferential issue diluted minorities, negligible dividend, family on board |
| Growth | 5.0/6 | ||
| 13 | Structural tailwind? | 1 | Solar grows far faster than GDP; multi-year policy push |
| 14 | Volume-led growth? | 1 | Driven by capacity (200 MW → 5.5 GW), not just price |
| 15 | Operating leverage? | 1 | OPM expanded 6% → 13% as sales 10x’d |
| 16 | Manageable leverage? | 0.5 | Net D/E ~0.5x now, but gross borrowings (₹888 cr) ≈ net worth (₹807 cr); peak debt ₹1,500 cr coming |
| 17 | Market-share gain? | 0.5 | Gaining, but tiny vs 12–20 GW integrated giants |
| 18 | Earnings growth >15%? | 1 | PAT CAGR ~131% (off a small base); guided 50–60% revenue growth ahead |
| Longevity | 3.5/5 | ||
| 19 | Relevant 10–15 yrs? | 0.5 | Solar demand durable; module tech & margin fragile (TOPCon → tandem; commoditizes) |
| 20 | Extend competitive-advantage period? | 0.5 | Moat thin today; integration could build a cost edge — unproven |
| 21 | Sustain growth-advantage period? | 1 | Long runway — Indian solar penetration low |
| 22 | Diversification headroom? | 1 | Cell, frame, wafer, ingot, BESS, EPC, IPP — lots of optionality (also “diworsification” risk) |
| 23 | Adaptive, resilient culture? | 0.5 | No cycle track record yet; default |
| Business-quality total | 15.5/23 | Quality 7.0 + Growth 5.0 + Longevity 3.5 | |
| 24 | Valuation reasonable (PEG)? | 1 | PEG ~0.2–0.4 (P/E 12.8 vs 50–60%+ growth) |
| 25 | Margin of safety (payback/PEG <1x)? | 1 | PEG well under 1; 5-yr payback ~1.1x |
| Price pillar | 2/2 | Reported separately — today’s reading, not the business | |
| Canonical QGLP (for fidelity) | 17.5/25 | Headline is the 15.5/23 business score |
The pillar pattern: Growth is the engine and it’s genuinely strong; Longevity is decent on runway but weak on durability of economics; Quality is the soft spot — specifically capital intensity (Q5), thin moat (Q3), and a brutal industry structure (Q2). The checklist likes this company because the checklist rewards growth and cheapness, which this has in spades. That’s exactly where it parts ways with Buffett.
Buffett lens (the Berkshire-letters read)
| # | Test | Verdict | Evidence |
|---|---|---|---|
| 1 | Good boat? (business > management) | PARTIAL | ”Good” not “Great” — decent RoCE but heavy reinvestment; commodity product. “A good managerial record is far more a function of what boat you get into.” |
| 2 | Moat + franchise + pricing power | FAIL | Non-DCR price is a $/W price-take (₹13–14); margins propped by policy, not franchise |
| 3 | See’s test — high returns on little capital | FAIL | Capital sink: capex ₹2,500 cr, FCF −₹521 cr. See’s threw off cash; this swallows it |
| 4 | Capital allocation — one-dollar test | PARTIAL | Retained + borrowed heavily at high RoE, but unproven through a cycle; market value created then halved |
| 5 | Owner-oriented, candid management | PARTIAL | No selling/pledge, modest pay (good); but promotional, sprawling guidance, thin board (caution) |
| 6 | Integrity / no “credit P&L, debit balance sheet” | FAIL | 5-yr OCF ₹78 cr vs PAT ₹400 cr; OCF −₹73 cr last year; receivables +156%. Profit isn’t becoming cash |
| 7 | Circle of competence / predictability | PARTIAL | Demand predictable; margins and tech are not. “If there’s lots of technology, we won’t understand it.” |
| 8 | Mr. Market — gift or trap? | PARTIAL | Cheap (P/E 13, −58% from high) — fearful pricing, but cheap for real reasons |
| 9 | Patience / compounding runway | PARTIAL | Long runway at high RoE if sustained at scale — the open question |
| 10 | The honest red flag | (prose below) | — |
PASS-equivalent ≈ 3 / 9 (six PARTIALs at ½ + two FAILs + one FAIL ≈ 3). Below 5 — “not in the temple, whatever the price.” Buffett would admire the founders’ skin in the game and pass on the business.
The See’s test, spelled out. See’s Candies cost $25m, needed only $32m more over 35 years, and threw off $1.35bn. Insolation is the photographic negative: to grow it must feed capital, not harvest it — ₹554 cr of investing outflow in FY25, ₹186 cr in FY26, with free cash flow of minus ₹521 cr last year. This is a business that, to run, must keep raising money. That can still make an owner rich if the returns on that capital stay high — but it is the “Good” (capital-hungry) box, not the “Great” (cash-fountain) box, and in a downturn the capital hunger is what bites.
The one-dollar test, spelled out. Has each retained (and borrowed) rupee created a rupee of value? On accounting returns, yes so far — RoE has stayed ~28% through the growth, and economic profit is positive at +₹131 cr (earning well above the 12% cost of equity). But the market-value half of the test is unflattering: the stock is down ~58% from its high. The honest reading is that the first rupees (the small SME-era plant) created enormous value, and the current rupees (the giant debt-funded cell bet) are an open verdict. We won’t know until the cell plant runs whether this round of retention clears the bar.
The framework metrics
- Economic Profit = ₹807 cr net worth × (28.2% − 12%) = +₹131 cr — creating value above the cost of owners’ money (on accounting RoE; the cash-conversion caveat above is the asterisk).
- Terms of Trade = debtor days 48 / payable days 62 ≈ 77% — favourable on days, but the +66-day cash-conversion cycle means it still ties up working capital as it grows.
- 5-yr Payback = ₹2,577 cr ÷ projected 5-yr cumulative PAT ≈ 1.1x (assuming 30% PAT CAGR; 0.95x at 35%, 1.25x at 25%) — near the multi-bagger threshold if growth holds.
- PEG = 12.8 ÷ ~50 = ~0.25 (≈0.37 on a conservative 35% forward) — well under 1; price discipline satisfied.
- RoE − CoE spread = +16.2% — large; RoE >15% in ~4 of the last 4 reported years (history too short for the 7-of-10 test).
- Consistent vs Volatile = Volatile — only 4–5 years of data, a cyclical commodity product; value this on P/B, not P/E, per the studies.
CoE assumed 12% (the studies’ mid-point); growth assumptions stated inline.
Peer comparison
| Company | Mkt cap | P/E | P/B | RoE | RoCE | OPM | Sales (FY26) |
|---|---|---|---|---|---|---|---|
| Insolation Energy | ₹2,577 cr | 12.8 | 3.2 | 28.2% | 22.2% | 13% | ₹2,146 cr |
| Waaree Energies | ₹89,900 cr | 22.9 | 6.2 | 32.8% | 38.8% | 22% | ₹26,537 cr |
| Premier Energies | ₹49,000 cr | 32.5 | 11.4 | 42.4% | 33.3% | 30% | ₹7,824 cr |
| Websol Energy | ₹4,546 cr | 15.0 | 7.2 | 66.9% | 63.2% | 41% | ₹1,049 cr |
| Vikram Solar | ₹7,262 cr | 15.3 | 2.3 | 21.5% | 30.5% | 19% | ₹4,802 cr |
Two things jump out. Insolation is the cheapest in the room (P/E 12.8) and has the thinnest margin (OPM 13%) — and those two facts are the same fact. The market is paying up for integration (cells), and discounting assembly (modules). Every peer with a higher margin has a cell base; Websol’s 41% margin on a smaller revenue base is the cleanest proof that the cell premium is real and large. Insolation’s distinctive position is that it’s the integration story you can still buy cheaply — a 13× module-assembler building toward the 20–40% margins its peers already earn. The relative read therefore flips the absolute one: on its own merits the price is fair-to-cheap; relative to its asset class it’s the value option precisely because it hasn’t yet proven the integration the others have. Cheap-with-a-reason, in one table.
Latest quarter & what’s happening now
Q4 FY26, reported 27 May 2026. A blowout quarter: revenue ₹794 cr (+100% YoY), EBITDA ₹111 cr, PAT ₹70 cr. Full-year FY26: revenue ₹2,146 cr (+61%), PAT ₹201 cr (+59%), EBITDA margin 14%. Mainboard listing completed 9 March 2026. Concall takeaways: (1) the 4.5 GW TOPCon cell plant is the centrepiece — COD targeted Q4 FY27, ramping to full by FY28, expected to lift margins to 20%+ [MEDIUM — management guidance]; (2) peak debt ~₹1,500 cr this year, FCF turning positive 6–8 months post-commissioning [MEDIUM]; (3) ALMM List-II for cells effective 1 June 2026 — management’s repeated “let’s see how the market settles after 1 June” is the one note of genuine caution in an otherwise bullish call [HARD that the rule is live; MEDIUM on impact]; (4) FY28 revenue target >₹5,000 cr [SOFT].
Where the two lenses agree — and disagree
They agree on the facts: a fast-growing, founder-aligned, cheap, capital-hungry manufacturer riding a policy tailwind.
They disagree sharply on the verdict, and that disagreement is the whole report. QGLP scores it a respectable 15.5/23 with a perfect 2/2 on price — because QGLP rewards growth, runway, and cheapness, and this has all three. Buffett scores it ~3/9 — a pass — because the letters weight moat, capital intensity, and cash conversion far harder, and this fails all three: no franchise (test 2), a capital sink not a cash fountain (test 3), and profit that isn’t becoming cash (test 6). Trust the divergence. When a checklist says “buy the growth” and the Berkshire letters say “this is a commodity boat that eats capital and whose profit you can’t yet spend,” the letters are pointing at the risk the checklist’s growth-love hides. The reconciliation: this could be a fine trade on a cheap, growing, policy-protected name, and a poor forever-holding — and those are different questions.
The price as a current phenomenon
This judges the price, not the business — the business verdict above is already settled.
The margin-of-safety band. On the raw framework arithmetic, the price pillar is already satisfied — PEG ~0.25 and payback ~1.1x say “cheap.” But this is a Volatile business (value it on book and through-cycle earnings, not peak), so we haircut for cyclicality and execution risk. That puts a sensible accumulation band at roughly ₹90–₹130 — below ~₹90 you’re paying close to book (₹37) plus a modest multiple for a profitable grower, which is a real margin of safety; above ~₹130 you’re increasingly paying for a cell plant that hasn’t run. CMP ₹117 sits mid-band: fair, leaning cheap if you believe the integration, ordinary if you don’t.
Mr. Market’s mood. Fearful — and revealingly so. The stock is down ~58% from ₹282 while profit rose 60%. That gap is the signature of an SME-era boom-and-bust unwinding (a 7× run on a thin BSE-SME line, then a froth-crash), layered on genuine worry about a solar manufacturing glut. Crucially, it is not a fundamental collapse — earnings compounded, promoters didn’t sell, pledging is zero. So the fear is partly about the old froth and partly about a real industry risk.
The tension, plainly: a Good-not-Great, capital-hungry commodity manufacturer can be a perfectly good purchase at a fearful price — and that’s the case here. The price is doing the work the moat doesn’t. This reading can change next week — a cell-plant delay or a margin scare — without one thing in the business changing.
Conviction texture
The bull case, at its strongest: You’re buying a 60%-growing solar manufacturer at 13× earnings — cheaper than every integrated peer — exactly as it executes the one move (own cells) that turns a 14% margin into a 20%+ margin, into a market that just made Indian cells mandatory for government projects (1 June 2026). Founders own 66%, pledged nothing, sold nothing, and bought more. If the cell plant lands on time, margins re-rate, free cash turns positive, and the stock that fell 58% on froth-unwind looks absurdly cheap in hindsight. Payback ~1.1x and economic profit +₹131 cr say the value creation is real.
The bear case, at its strongest (the honest red flag): This is a sub-scale assembler of a commodity product, in an industry its own regulator is warning is a bubble (165 GW capacity, 50 GW demand), carrying an 8× debt build for an unproven plant, against integrated giants 4–15× its size with PLI money. Profit isn’t becoming cash (₹78 cr OCF on ₹400 cr of 5-year profit), receivables are ballooning, the board’s independence is thin, and there’s a live interest-capitalization question that may be flattering the very profit you’re paying 13× for. China shows what an unprotected, overbuilt module business does — sells below cost, billions in losses — and India is building toward the same oversupply just as the cell-scarcity rent that justifies the plant is set to fade. ICRA already forecasts the small/pure-play module makers getting consolidated away. Insolation is in that exact cohort.
What the numbers actually support: A genuinely cheap, genuinely fast-growing manufacturer making a sensible-but-risky integration bet, with clean promoter alignment and a real cash-conversion concern. Not a Great business; a Good one with a clock on it. The three things that tip it: (1) the cell plant commissioning on time, (2) operating cash flow turning decisively positive, and (3) the blended margin walking from 14% toward 20%. Watch those, in that order. No buy/sell/hold — the framework’s output is a quality verdict (Good, leaning Gruesome; Transitory; Volatile), a price band (₹90–130, CMP fair), and these two honest sides.
Sources
- Screener: https://www.screener.in/company/INA/consolidated/ (snapshot 2026-06-20)
- Q4/FY26 concall, 27 May 2026; Q3/9M FY26 concall, 17 Feb 2026 (BSE filings)
- FY25 & FY24 annual reports (BSE/company filings)
- Policy/competition: pv-magazine, pv-tech, CSIS, taiyangnews, ICRA, Woodmac, Mercom, SaurEnergy, Energetica India (2025–26, dated inline)
- Management/governance: Mercom (preferential issue, 17 Oct 2024; IREDA loan, 18 Sep 2025), Chittorgarh/IPOWatch (IPO), Business Standard (CFO change, 24 Mar 2025), Trendlyne (shareholding), SEBI disclosures
- Assumptions: Cost of Equity 12%; PAT CAGR 25–35% range for payback; all growth stated inline. Peer figures from each peer’s screener snapshot (2026-06-20).